



Clinical trial results:

A comparison of Symbicort Single inhaler Therapy (Symbicort Turbohaler 160/4.5 g, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26-week, randomised, open-label, parallel-group, multi-centre study (SALTO)

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2004-001107-36 |
| Trial protocol | BE |
| Global end of trial date | 20 June 2008 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v2 (current) |
| This version publication date | 08 July 2016 |
| First version publication date | 28 April 2016 |
| Version creation reason | |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | D5890L00009 |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | AstraZeneca |
| Sponsor organisation address | AstraZeneca NV/SA, B-1180 Brussels, Belgium, |
| Public contact | Guy Vandenhoven MD, AstraZeneca, ClinicalTrialTransparency@astrazeneca.com |
| Scientific contact | Guy Vandenhoven MD, AstraZeneca, ClinicalTrialTransparency@astrazeneca.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 20 June 2008 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 20 June 2008 |
| Global end of trial reached? | Yes |
| Global end of trial date | 20 June 2008 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study was to compare the efficacy of SMART (Symbicort Turbohaler 160/4.5µg, 1 inhalation b.i.d. + as needed in response to symptoms) with treatment according to conventional best practice in adolescent and adult patients with persistent asthma.

The primary efficacy variable was the time to first severe asthma exacerbation.

Protection of trial subjects:

The final study protocol, including the final version of the Informed Consent Form, was approved or given a favourable opinion in writing by an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) as appropriate. The investigator submitted written approval to AstraZeneca NV/SA before enrolling any patient into the study.

The principal investigator(s) at each centre ensured that the patient was given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Patients were also notified that they were free to discontinue from the study at any time. The patients were given the opportunity to ask questions and allowed time to consider the information provided.

In patients below the age of consent, informed consent was obtained from both the patient and the patient's parent/legal guardian. The patient's signed and dated informed consent was obtained before conducting any study-specific procedure

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 15 December 2004 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------|
| Country: Number of subjects enrolled | Belgium: 912 |
| Worldwide total number of subjects | 912 |
| EEA total number of subjects | 912 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |

| | |
|--|-----|
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 64 |
| Adults (18-64 years) | 724 |
| From 65 to 84 years | 122 |
| 85 years and over | 2 |

Subject disposition

Recruitment

Recruitment details:

The study consisted of 912 randomised patients from Belgium between December 2004 and January 2006.

Pre-assignment

Screening details:

The study consisted of five scheduled visits to the clinic: at the start of the run-in period, at randomisation to the treatment groups and after 4, 13 and 26 weeks of study. Patients were allocated to one of 2 treatment groups in a random manner.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-----------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Symbicort SMART |

Arm description:

Symbicort Turbohaler 160/4.5 µg, 1 inhalation b.i.d. plus as needed

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Symbicort Turbohaler: budesonide 160 µg/inhalation (delivered dose) and formoterol fumarate dehydrate 4.5 µg/inhalation (delivered dose) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Inhalation powder |
| Routes of administration | Inhalation use |

Dosage and administration details:

160/4.5 µg, 1 inhalation b.i.d. plus as needed

| | |
|------------------|----------------------------------|
| Arm title | Conventional Best Practice (CBP) |
|------------------|----------------------------------|

Arm description:

Conventional Best Practice

| | |
|---|-----------------|
| Arm type | No intervention |
| No investigational medicinal product assigned in this arm | |

| Number of subjects in period 1 | Symbicort SMART | Conventional Best Practice (CBP) |
|--------------------------------|-----------------|----------------------------------|
| Started | 452 | 460 |
| Completed | 423 | 444 |
| Not completed | 29 | 16 |
| Consent withdrawn by subject | 4 | 1 |
| Adverse event, non-fatal | 4 | 2 |
| Other | 4 | 1 |
| Lost to follow-up | 5 | 3 |

| | | |
|--------------------|----|---|
| Protocol deviation | 12 | 9 |
|--------------------|----|---|

Baseline characteristics

Reporting groups

| | |
|---|----------------------------------|
| Reporting group title | Symbicort SMART |
| Reporting group description: Symbicort Turbohaler 160/4.5 µg, 1 inhalation b.i.d. plus as needed | |
| Reporting group title | Conventional Best Practice (CBP) |
| Reporting group description: Conventional Best Practice | |

| Reporting group values | Symbicort SMART | Conventional Best Practice (CBP) | Total |
|--|-----------------|----------------------------------|-------|
| Number of subjects | 452 | 460 | 912 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 32 | 32 | 64 |
| Adults (18-64 years) | 358 | 366 | 724 |
| From 65-84 years | 61 | 61 | 122 |
| 85 years and over | 1 | 1 | 2 |
| Age continuous Units: years | | | |
| arithmetic mean | 43.4 | 42.9 | |
| full range (min-max) | 12 to 87 | 13 to 85 | - |
| Gender categorical Units: Subjects | | | |
| Female | 253 | 271 | 524 |
| Male | 199 | 189 | 388 |
| Median time since diagnosis Units: years | | | |
| median | 21 | 20.3 | |
| full range (min-max) | 0 to 86 | 0 to 78 | - |

End points

End points reporting groups

| | |
|---|----------------------------------|
| Reporting group title | Symbicort SMART |
| Reporting group description: | |
| Symbicort Turbohaler 160/4.5 µg, 1 inhalation b.i.d. plus as needed | |
| Reporting group title | Conventional Best Practice (CBP) |
| Reporting group description: | |
| Conventional Best Practice | |

Primary: No of patients with severe exacerbations

| | |
|------------------------|--|
| End point title | No of patients with severe exacerbations |
| End point description: | |
| End point type | Primary |
| End point timeframe: | |
| 26 weeks | |

| End point values | Symbicort SMART | Conventional Best Practice (CBP) | | |
|-----------------------------|-----------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 452 | 460 | | |
| Units: patients | 12 | 19 | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Time to first severe Exacerbation |
| Comparison groups | Conventional Best Practice (CBP) v Symbicort SMART |
| Number of subjects included in analysis | 912 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.2347 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.645 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.313 |
| upper limit | 1.329 |

Secondary: Number of severe exacerbations

| | |
|-----------------|--------------------------------|
| End point title | Number of severe exacerbations |
|-----------------|--------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

26 weeks

| End point values | Symbicort SMART | Conventional Best Practice (CBP) | | |
|------------------------------------|-----------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 452 | 460 | | |
| Units: patients with exacerbations | | | | |
| No, of patients with 1 event | 10 | 15 | | |
| No, of patients with 2 events | 2 | 3 | | |
| No, of patients with 3 events | 0 | 0 | | |
| No, of patients with >3 events | 0 | 1 | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Mean number of severe asthma exacerbations |
| Comparison groups | Symbicort SMART v Conventional Best Practice (CBP) |
| Number of subjects included in analysis | 912 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0029 |
| Method | Poisson Regression |
| Parameter estimate | Risk ratio (RR) |
| Point estimate | 0.5754 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.4 |
| upper limit | 0.83 |

Secondary: Average number of inhalations per day

| | |
|-----------------|---------------------------------------|
| End point title | Average number of inhalations per day |
|-----------------|---------------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

26 weeks

| End point values | Symbicort SMART | Conventional Best Practice (CBP) | | |
|--|------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 445 | 457 | | |
| Units: average inhalations per day | | | | |
| arithmetic mean (full range (min-max)) | 0.93 (0 to 6.95) | 0.99 (0 to 10.4) | | |

Statistical analyses

| Statistical analysis title | Average no of inhalations per day |
|---|--|
| Comparison groups | Symbicort SMART v Conventional Best Practice (CBP) |
| Number of subjects included in analysis | 902 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.1471 |
| Method | ANOVA |
| Parameter estimate | Mean difference (net) |
| Point estimate | -0.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.24 |
| upper limit | 0.04 |

Secondary: As needed free-days

| | |
|------------------------|--|
| End point title | As needed free-days |
| End point description: | Percentage of days without medication use during the treatment period. |
| End point type | Secondary |
| End point timeframe: | |
| 26 weeks | |

| End point values | Symbicort SMART | Conventional Best Practice (CBP) | | |
|--|-------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 445 | 457 | | |
| Units: Percentage use | | | | |
| arithmetic mean (full range (min-max)) | 60.5 (0 to 102.4) | 62.4 (0 to 114.3) | | |

Statistical analyses

| Statistical analysis title | As needed free-days |
|--|--|
| Statistical analysis description: | |
| Percentage of as needed medication free days in the treatment period | |
| Comparison groups | Symbicort SMART v Conventional Best Practice (CBP) |
| Number of subjects included in analysis | 902 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.5108 |
| Method | ANOVA |
| Parameter estimate | Mean difference (net) |
| Point estimate | -1.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.77 |
| upper limit | 2.38 |

Secondary: Mean daily dose of inhaled steroids

| | |
|------------------------|-------------------------------------|
| End point title | Mean daily dose of inhaled steroids |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 26 weeks | |

| End point values | Symbicort SMART | Conventional Best Practice (CBP) | | |
|--|-------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 452 | 460 | | |
| Units: µg | | | | |
| arithmetic mean (full range (min-max)) | 482 (329 to 1473) | 589 (247 to 2000) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Mean daily dose of inhaled steroids |
| Comparison groups | Symbicort SMART v Conventional Best Practice (CBP) |
| Number of subjects included in analysis | 912 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | ANOVA |
| Parameter estimate | Mean difference (net) |
| Point estimate | -107.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -141.2 |
| upper limit | -73.76 |

Secondary: PEF pre-BD at end of treatment

| | |
|------------------------|--------------------------------|
| End point title | PEF pre-BD at end of treatment |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 26 weeks | |

| | | | | |
|--|--------------------|----------------------------------|--|--|
| End point values | Symbicort SMART | Conventional Best Practice (CBP) | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 452 | 460 | | |
| Units: L/min | | | | |
| arithmetic mean (full range (min-max)) | 423.72 (85 to 748) | 417.84 (60 to 763) | | |

Statistical analyses

| | |
|-----------------------------------|--|
| Statistical analysis title | PEF pre-BD at end of treatment |
| Comparison groups | Symbicort SMART v Conventional Best Practice (CBP) |

| | |
|---|-----------------------|
| Number of subjects included in analysis | 912 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.5991 |
| Method | ANOVA |
| Parameter estimate | Mean difference (net) |
| Point estimate | 2.13 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.81 |
| upper limit | 10.07 |

Secondary: PEF post-BD at end of treatment

| | |
|------------------------|---------------------------------|
| End point title | PEF post-BD at end of treatment |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 26 weeks | |

| End point values | Symbicort SMART | Conventional Best Practice (CBP) | | |
|--|---------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 452 | 460 | | |
| Units: L/min | | | | |
| arithmetic mean (full range (min-max)) | 446.36 (100 to 770) | 442.83 (100 to 804) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | PEF post-BD at end of treatment |
| Comparison groups | Symbicort SMART v Conventional Best Practice (CBP) |
| Number of subjects included in analysis | 912 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.6537 |
| Method | ANOVA |
| Parameter estimate | Mean difference (net) |
| Point estimate | 1.68 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.65 |
| upper limit | 9 |

Secondary: FEV1 pre-BD at end of treatment

| | |
|------------------------|---------------------------------|
| End point title | FEV1 pre-BD at end of treatment |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 26 weeks | |

| End point values | Symbicort SMART | Conventional Best Practice (CBP) | | |
|--|-------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 137 | 136 | | |
| Units: L/min | | | | |
| arithmetic mean (full range (min-max)) | 2.76 (0.9 to 6.2) | 2.87 (0.7 to 6) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | FEV1 pre-BD at end of treatment |
| Comparison groups | Symbicort SMART v Conventional Best Practice (CBP) |
| Number of subjects included in analysis | 273 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.4135 |
| Method | ANOVA |
| Parameter estimate | Mean difference (net) |
| Point estimate | -0.004 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.12 |
| upper limit | 0.05 |

Secondary: FEV1 post-BD at end of treatment

| | |
|-----------------|----------------------------------|
| End point title | FEV1 post-BD at end of treatment |
|-----------------|----------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

26 weeks

| End point values | Symbicort SMART | Conventional Best Practice (CBP) | | |
|--|-------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 137 | 136 | | |
| Units: L/min | | | | |
| arithmetic mean (full range (min-max)) | 2.91 (0.9 to 6.3) | 3 (0.8 to 6) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | FEV1 post-BD at end of treatment |
| Comparison groups | Symbicort SMART v Conventional Best Practice (CBP) |
| Number of subjects included in analysis | 273 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.3285 |
| Method | ANOVA |
| Parameter estimate | Mean difference (net) |
| Point estimate | -0.004 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.12 |
| upper limit | 0.03 |

Secondary: Mean overall ACQ score

| | |
|-----------------|------------------------|
| End point title | Mean overall ACQ score |
|-----------------|------------------------|

End point description:

Mean ACQ score (overall) during the treatment period

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

26 weeks

| End point values | Symbicort SMART | Conventional Best Practice (CBP) | | |
|--|-----------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 446 | 451 | | |
| Units: mean score | | | | |
| arithmetic mean (full range (min-max)) | 1.1 (0 to 4.2) | 1.16 (0 to 5.2) | | |

Statistical analyses

| Statistical analysis title | Change in ACQ score |
|--|--|
| Statistical analysis description: | |
| Change in mean ACQ score (overall) during the treatment period | |
| Comparison groups | Symbicort SMART v Conventional Best Practice (CBP) |
| Number of subjects included in analysis | 897 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0026 |
| Method | ANOVA |
| Parameter estimate | Mean difference (net) |
| Point estimate | -0.12 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.2 |
| upper limit | -0.04 |

Secondary: Mean overall SATQ score

| End point title | Mean overall SATQ score |
|--|-------------------------|
| End point description: | |
| Satisfaction with Asthma Treatment Questionnaire (SATQ) : to measure patients satisfaction with their inhaled asthma medication. It consists of 26 questions on a 7 point scale within 4 domains (effectiveness, ease of use, burden of asthma medication, side effects and worries). Higher scores indicates satisfaction with inhaled asthma medication. | |
| End point type | Secondary |
| End point timeframe: | |
| 26 weeks | |

| End point values | Symbicort SMART | Conventional Best Practice (CBP) | | |
|--|-------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 421 | 421 | | |
| Units: mean score | | | | |
| arithmetic mean (full range (min-max)) | 4.81 (3.1 to 6.3) | 4.82 (3.4 to 6.6) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Change in SATQ score |
| Comparison groups | Symbicort SMART v Conventional Best Practice (CBP) |
| Number of subjects included in analysis | 842 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.5039 |
| Method | ANOVA |
| Parameter estimate | Mean difference (net) |
| Point estimate | -0.02 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.08 |
| upper limit | 0.04 |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Only information regarding SAEs, and discontinuations due to AE was collected, from the run-in period until visit 5 (26 weeks after randomisation).

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|-----|
| Dictionary version | 7.0 |
|--------------------|-----|

Reporting groups

| | |
|-----------------------|----------------------------------|
| Reporting group title | Conventional Best Practice (CBP) |
|-----------------------|----------------------------------|

Reporting group description:

Conventional Best Practice

| | |
|-----------------------|-----------------|
| Reporting group title | Symbicort SMART |
|-----------------------|-----------------|

Reporting group description:

Symbicort Turbohaler 160/4.5 µg, 1 inhalation b.i.d. plus as needed

| Serious adverse events | Conventional Best Practice (CBP) | Symbicort SMART | |
|---|----------------------------------|------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 12 / 460 (2.61%) | 10 / 452 (2.21%) | |
| number of deaths (all causes) | 0 | 2 | |
| number of deaths resulting from adverse events | 0 | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Breast Cancer | | | |
| subjects affected / exposed | 1 / 460 (0.22%) | 0 / 452 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myelodysplastic Syndrome | | | |
| subjects affected / exposed | 0 / 460 (0.00%) | 1 / 452 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine Leiomyoma | | | |
| subjects affected / exposed | 1 / 460 (0.22%) | 0 / 452 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Transient Ischaemic Attack | | | |

| | | | |
|--|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 460 (0.22%) | 0 / 452 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 460 (0.00%) | 1 / 452 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Immune system disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 1 / 460 (0.22%) | 2 / 452 (0.44%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Reproductive system and breast disorders | | | |
| Salpingitis | | | |
| subjects affected / exposed | 1 / 460 (0.22%) | 1 / 452 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign Prostatic Hyperplasia | | | |
| subjects affected / exposed | 1 / 460 (0.22%) | 0 / 452 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 460 (0.00%) | 1 / 452 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Myocardial Infarction | | | |
| subjects affected / exposed | 1 / 460 (0.22%) | 1 / 452 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Nervous system disorders | | | |

| | | | |
|---|-----------------|-----------------|--|
| Cerebrovascular Accident | | | |
| subjects affected / exposed | 1 / 460 (0.22%) | 0 / 452 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Facial Palsy | | | |
| subjects affected / exposed | 0 / 460 (0.00%) | 1 / 452 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ear and labyrinth disorders | | | |
| Labyrinthine Fistula | | | |
| subjects affected / exposed | 1 / 460 (0.22%) | 0 / 452 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Gastric Ulcer | | | |
| subjects affected / exposed | 0 / 460 (0.00%) | 1 / 452 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholecystitis | | | |
| subjects affected / exposed | 2 / 460 (0.43%) | 0 / 452 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Urethral Meatus Stenosis | | | |
| subjects affected / exposed | 1 / 460 (0.22%) | 0 / 452 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Intervertebral Disc Protusion | | | |
| subjects affected / exposed | 0 / 460 (0.00%) | 1 / 452 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Pneumonia | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 460 (0.00%) | 1 / 452 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Conventional Best Practice (CBP) | Symbicort SMART | |
|---|----------------------------------|-----------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1 / 460 (0.22%) | 1 / 452 (0.22%) | |
| Cardiac disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 460 (0.00%) | 1 / 452 (0.22%) | |
| occurrences (all) | 0 | 1 | |
| Nervous system disorders | | | |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 460 (0.00%) | 1 / 452 (0.22%) | |
| occurrences (all) | 0 | 1 | |
| Gastrointestinal disorders | | | |
| Pharyngolaryngeal Pain | | | |
| subjects affected / exposed | 1 / 460 (0.22%) | 0 / 452 (0.00%) | |
| occurrences (all) | 1 | 0 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported